Abstract:Clinical studies have shown that insulin receptor (IR) and the insulin-like growth factor(IGF)-1-receptor (IGF-1R) signaling are largely reduced in the brains of patients suffering from Alzheimer's disease (AD) and other neurodegenerative diseases. Whether the impaired IR/IGF-1R signaling is cause, consequence or even counterregulation to neurodegeneration and whether the accompanying changes in IR/IGF-1R mediated transcription are involved in the pathogenesis of AD is currently a matter of debate. Recent studies have shown that IGF-1 resistance induces Ab hyperaggregation leading to Ab-detoxification and rescues the increased mortality of APP (amyloid precursor protein) overexpressing mice. Since FoxO transcription factors are highly likely candidates to mediate these effects, two mouse strains have been established, one expressing a constitutively active FoxO1 mutant (FoxO1ADA), the other a dominant negative mutant FoxO1 (FoxO1DN). To analyse the role of FoxO1 mediated transcription for AD pathology Tg2576 mice overexpressing the human derived mutant APP form (APPsw) with a size of 695 amino acids were used. This APP variant harbours an amino acid substitution of Lys670 to Asn and Met671 to Leu, so called “swedish mutation” (APPsw) leading to an increased generation of Aβ. Mice expressing neuronspecifically the dominant negative (FoxO1DN) or the constitutive active form of FoxO1 (FoxO1ADA) were crossed with Tg2576 mice. The different genotypes (wild-type, FoxO1DN, Tg2576/FoxO1DN, FoxO1ADA, Tg2576/FoxO1ADA and Tg2576 mice) were used to analyse glucose metabolism, insulin and IGF-1 signaling, survival (Kaplan-Meier) and APP processing up to 60 weeks of age. Mice in Tg2576 background displayed unaltered glucose homeostasis. Furthermore, Kaplan-Meier analysis revealed no differences in survival of Tg2576/FoxO1DN female and male mice compared to Tg2576 mice. Surprisingly, Tg2576/FoxO1ADA female mice showed an increase of premature death in comparison with Tg2576 female mice without reaching statistical significance. Interestingly Tg2576/FoxO1ADA male mice did not live longer than 16 weeks. Additionally, western blot analysis from brain lysates of the different genotypes did not reveal alteration of the IR/IGF- 1R signaling pathway. Processing of APP in Tg2576/FoxO1DN and Tg2576/FoxO1ADA mice was unchanged compared to Tg2576 mice. The level of a/bCTFs as well as Ab40 and Ab42 burden revealed no differences in the genotypes with AD background. Furthermore, accumulation of Ab oligomers was not influenced by FoxO1 mediated transcription. The results of the current study exclude FoxO1 mediated transcription as the underlying mechanism of the beneficial effects of IGF-1 resistance on AD pathology in Tg2576 mice.

Genetic Reduction of Insulin Signaling Mitigates Amyloid-β Deposition by Promoting Expression of Extracellular Matrix Proteins in the Brain

Deregulation of Brain Insulin Signaling in Alzheimer’s Disease

219-OR: Loss of Insulin Signaling in Microglia Impairs Cellular Uptake of Aß and Neuroinflammatory Response Exacerbating Alzheimer-Like Neuropathology

Loss of Insulin Signaling in Microglia Impairs Cellular Uptake of Aβ and Neuroinflammatory Response Exacerbating Alzheimer-like Neuropathology

Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe/PS1dE9 mice.

Targeting Insulin Signaling for the Treatment of Alzheimer's Disease.

Loss of insulin signaling in astrocytes exacerbates Alzheimer-like phenotypes in a 5xFAD mouse model

Insulin Deficiency Increases Sirt2 Level in Streptozotocin-Treated Alzheimer’s Disease-Like Mouse Model: Increased Sirt2 Induces Tau Phosphorylation Through ERK Activation

Immunoproteasome Subunit Low Molecular Mass Peptide 2 (LMP2) Deficiency Ameliorates LPS/Aβ1-42-Induced Neuroinflammation

Age-Dependent Changes in the Plasma and Brain Pharmacokinetics of Amyloid-β Peptides and Insulin

Impaired neuronal insulin signaling precedes Aβ42 accumulation in female AβPPsw/PS1ΔE9 mice.

Insulin-Like Growth Factor Signaling in Alzheimer's Disease: Pathophysiology and Therapeutic Strategies

Changes in the Extracellular Matrix with Aging: A Larger Role in Alzheimer's Disease

Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer’s disease: possible mechanisms of IDE in T2D and AD

Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer’s disease

Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway

The role of FoxO1 in neurodegenerative diseases

1-Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance

Microglia Do Not Take Up Soluble Amyloid-beta Peptides, But Partially Degrade Them by Secreting Insulin-degrading Enzyme

Amino Acid Compound 2 (AAC2) Treatment Counteracts Insulin-Induced Synaptic Gene Expression and Seizure-Related Mortality in a Mouse Model of Alzheimer's Disease